Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.

doi:10.1002/cncr.33148

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.

Cancer - 15 Dec 2020

Feldman Darren R, Ged Yasser, Lee Chung-Han, Knezevic Andrea, Molina Ana M, Chen Ying-Bei, Chaim Joshua, Coskey Devyn T, Murray Samuel, Tickoo Satish K, Reuter Victor E, Patil Sujata, Xiao Han, Aghalar Jahan, Apollo Arlyn J, Carlo Maria I, Motzer Robert J, Voss Martin H

Abstract excerpt

BACKGROUND: We previously reported on a phase 2 study of everolimus plus bevacizumab across various nonclear cell renal cell carcinoma (nccRCC) histologies and observed encouraging activity among patients with papillary RCC (pRCC) and unclassified RCC (uRCC) with a major papillary component. We subsequently expanded the study to enroll additional patients with pRCC variants. METHODS: Everolimus plus bevacizumab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Carcinoma, Renal Cell

Share to Everolimus

Share to Fumarate Hydratase

Share to Kidney Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32975815
DOI: 10.1002/cncr.33148
PMCID: PMC8366407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.PMID 32975815Read ↗

Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.Semantic proximity Read ↗

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.Semantic proximity Read ↗

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Semantic proximity Read ↗

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the LiteratureSemantic proximity Read ↗

Papillary renal cell carcinoma: A review of the current therapeutic landscape.Semantic proximity Read ↗

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

ELOC-Mutated Renal Cell Carcinoma is a Rare Indolent Tumor With Distinctive Genomic Characteristics.Semantic proximity Read ↗

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.Semantic proximity Read ↗

Papillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features.Semantic proximity Read ↗

Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.Semantic proximity Read ↗

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.